Longeveron vs ProKidney
LGVN and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGVN and PROK compare
ProKidney is the larger company, worth 4.0 times as much as Longeveron ($316M against $79.4M).
ProKidney grew revenue faster over the last twelve months (4.2% versus −18.9% for Longeveron).
Longeveron keeps more of each dollar of sales as profit, with a net margin of −1922% compared with −13327% at ProKidney.
Longeveron scores higher on the StockData Score (5 against 4 for ProKidney), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGVN | PROK |
|---|---|---|
| Size and price | ||
| Market cap | $79.4M | $316M |
| Share price | $2.49 | $1.04 |
| Change, 1 year | −64.8% | −61.0% |
| Change, 5 years | −99.8% | −89.5% |
| Beta (5Y) | 1.24 | 1.30 |
| Employees | 37 | 231 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 68.1× (better) | 408× |
| P/B | 16.9× | – |
| FCF yield | −22.9% (better) | −53.1% |
| Growth | ||
| Revenue growth (TTM) | −18.9% | 4.2% (better) |
| Revenue growth, 5Y average | −26.6% | – |
| Profitability | ||
| Gross margin | 66.4% | – |
| Operating margin | −2021% (better) | −24830% |
| Net margin | −1922% (better) | −13327% |
| FCF margin | −1560% (better) | −21655% |
| Return on equity | −305% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −10690.8× |
| Current ratio | 1.25 | 5.04 (better) |
| Altman Z-score | −17.08 | −5.65 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −5.4% |
| Shareholder yield | 0.00% (better) | −5.4% |
| Ownership | ||
| Held by institutions | 1.5% | 16.1% |
| Held by insiders | 43.8% | 62.9% |
| Insider net buying, 12 months | – | −$1.1M |
| Short interest, % of float | 0.88% | 21.7% |
Go deeper
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
- PROK stock overview
- PROK income statement
- PROK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.